The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world
- 1 December 2006
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 19 (6) , 607-614
Abstract
To describe surveillance measures to inform HIV drug-resistance prevention, as part of the public health approach to antiretroviral therapy in developing countries. Neither HIV drug-resistance transmission nor its emergence in treatment is routinely assessed in the developing world, but routine methods should be part of antiretroviral therapy scale-up. Mathematical modelling and experience in resource-rich countries suggest HIV drug-resistance transmission will increase as antiretroviral therapy coverage increases, but its rise will be limited initially. Transmission surveys should begin in geographic areas in each country where antiretroviral therapy coverage is widespread. Reports from resource-limited countries suggest that antiretroviral therapy programs are as effective as in resource-rich countries, which should limit HIV drug resistance if effectiveness is maintained with antiretroviral therapy expansion. Surveillance of HIV drug resistance emerging in treatment and other factors will support implementation of prevention measures on a population level. Standardized surveillance of transmitted and treatment-associated HIV drug resistance is critical to the success of antiretroviral therapy expansion in developing countries. Routine assessment of prescribing practices, availability of and access to appropriate regimens for adults and children, antiretroviral drug supply continuity, and measures to prevent HIV transmission will supply critical information for HIV drug-resistance prevention.Keywords
This publication has 50 references indexed in Scilit:
- Examining the production costs of antiretroviral drugsAIDS, 2006
- National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?AIDS, 2006
- Antiretroviral treatment of HIV infected adultsBMJ, 2006
- Free Antiretrovirals Must Not Be Restricted Only to Treatment-Naive PatientsPLOS Medicine, 2005
- Antiretroviral Therapy in Public and Private Routine Health Care Clinics in Cameroon: Lessons from the Douala Antiretroviral (DARVIR) InitiativeClinical Infectious Diseases, 2005
- HIV‐1 Drug Resistance: Degree of Underestimation by a Cross‐Sectional versus a Longitudinal Testing ApproachThe Journal of Infectious Diseases, 2005
- Molecular Characterization of HIV Type 1 Isolates from Untreated Patients of Mumbai (Bombay), India, and Detection of Rare Resistance MutationsAIDS Research and Human Retroviruses, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Protease Mutations in HIV-1 Non-B Strains Infecting Drug-Naive Villagers of CameroonAIDS Research and Human Retroviruses, 2004
- NOTES AND QUOTESAIDS, 2004